Seth Klarman acquired 6.59 Million Theravance Biopharma shares worth $61.3 Million. That's 2.00% of their equity portfolio (10th largest holding). The investor owns 13.12% of the outstanding Theravance Biopharma stock. The first Theravance Biopharma trade was made in Q2 2014. Since then Seth Klarman bought shares eight more times and sold shares on seven occasions. The investor's estimated purchase price is $154 Million, resulting in a loss of 60%.